China Sacubitril Hemicalcium artifices et instructores

Sacubitril Hemicalcium

Brevis descriptio:

API Nomen	Indicium	Specification	US DMF	EU DMF	CEP
Sacubitril Hemicalcium		In-Domus

Mitte ad nos inscriptio

Product Detail

Product Tags

Product SINGULA

沙库比曲半钙盐	Sacubitril Hemicalcium	1369773-39-6	In-Domus
沙库比曲钠盐		149690-05-1	In-Domus
LCZ-4		1426129-50-1	In-Domus
LCZ-7		1012341-48-8	In-Domus
LCZ-8		1012341-50-2	In-Domus
LCZ-9		149690-12-0	In-Domus

Background

AHU-377 Sal hemicalcium est hemicalcium salis forma AHU-377. Inhibitor neprilysin cum IC50 valore 5 nM [1] est.

AHU-377 et angiotensin II AT1 receptor antagonistam valsartanam componunt LCZ696 in ratione molari 1; LCZ696 receptor angiotensin neprilysin inhibitor est. Potest reducere sanguinem pressura et novum medicamentum ad cordis defectum curationem. AHU-377 pro-medicamentum est, ab enzymatica ethyl niensis in formam activam converti potest LBQ657. Ferunt AHU-377 (30 et 100 mg/kg, PO) effectum antihypertensivum causare posse in modo dosi dependens mures DAHI-SS. Sed in DOCA-sal hypertensiva mures infirma reductionem ostendit [2, 3].

Notae:
[1] Ksander GM, Ghai RD, Jesus R, Diefenbacher CG, Yuan A, Berry C, Sakane Y, Trapani A. Acidum Dicarboxylicum dipeptidum neutrum endopeptidasi inhibitores. J Med Chem. 1995 May 12; 38(10):1689-700.
[2] Voors AA, Dorhout B, van der Meer P. Partes potentiales valsartan + AHU377 (LCZ696) in curatione cordis defectio. Expert Opin Investig Medicamenta. 2013 Aug;22(8):1041-7.
[3] Laxminarayan G Hegde, Cecilia Yu, Cheruvu Madhavi et al. Efficacia comparativa de AHU-377, neprilysin inhibitoris potentis, in duobus exemplaribus hypertensionis tomi-dependens. BMC Pharmacology 2011, 11(Suppl 1):P33.